Table 1 Clinical characteristics of the enrolled participants
Clinical indexes | Control (n = 25) | Stone UR (n = 32) | Tumor UR (n = 25) | P-value Control vs Stone UR | P-value Control vs Tumor UR | P-value Stone UR vs Tumor UR |
|---|---|---|---|---|---|---|
Age (year) | 42.92 ± 20.15 | 52.94 ± 14.40 | 61.60 ± 13.24 | 0.054 | 0.0013 | 0.034 |
Gender | ||||||
 Female | 17 (68%) | 21 (65.62%) | 16 (64%) | 1 | 1 | 1 |
 Male | 8 (32%) | 11 (34.38%) | 9 (36%) | |||
DBIL (μmol/L) | 2.50 ± 0.70 | 4.14 ± 2.74 | 4.56 ± 5.61 | 0.030 | 0.25 | 0.49 |
IBIL (μmol/L) | 4.36 ± 1.85 | 6.53 ± 2.67 | 5.46 ± 2.76 | 0.043 | 0.58 | 0.12 |
eGFR | 97.56 ± 23.70 | 70.63 ± 32.19 | 40.30 ± 33.32 | 0.013 | 0.00010 | 0.0032 |
ALP (μ/L) | 91.08 ± 30.99 | 91.70 ± 33.98 | 144.92 ± 234.24 | 0.96 | 0.79 | 0.81 |
UA(μmol/L) | 317.20 ± 54.00 | 367.96 ± 103.13 | 454.01 ± 160.95 | 0.24 | 0.039 | 0.063 |
RBC (/μL) | 9.45 ± 10.60 | 691.23 ± 1348.03 | 3489.10 ± 6187.54 | 0.0015 | 0.068 | 0.56 |
WBC (/μL) | 55.45 ± 123.05 | 2110.97 ± 5085.15 | 1472.82 ± 3973.84 | 0.0096 | 0.0026 | 0.59 |
pH | ||||||
 > 6.5 | 2 (8%) | 12 (37.5%) | 7 (28%) | 0.27 | 0.68 | 0.56 |
 ≤ 6.5 | 9 (36%) | 17 (53.1%) | 16 (64%) | |||
Urobilinogen | ||||||
 Positive | 1 (4%) | 3 (9.4%) | 2 (8%) | 1 | 1 | 1 |
 Negative | 10 (40%) | 27 (84.4%) | 20 (80%) | |||
Proteinuria | ||||||
 Positive | 0 (0%) | 20 (62.5%) | 16 (64%) | 0.00016 | 0.000086 | 0.76 |
 Negative | 11 (44%) | 10 (31.2%) | 6 (24%) | |||